Novo Nordisk previews new EASD 2026 data on CagriSema, food cue reactivity and body composition. Learn what these preliminary abstracts mean for daily habits.
On September 16, 2026, Novo Nordisk announced it will present new research at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes. This meeting is scheduled for September 28 through October 2 in Milan. The pharmaceutical manufacturer says it will share 44 abstracts spanning semaglutide, CagriSema and zenagamtide programs. The upcoming sessions will examine appetite regulation, eating behavior and organ-level fat.
The central focus of this announcement is a preview of planned conference presentations rather than final clinical results. Novo Nordisk clearly states the accepted abstracts contain preliminary data that might change before final publication. This preview represents a notable shift in how the industry measures metabolic health. The conversation is moving away from total body weight to investigate changes in body composition.
One specific session is an oral presentation scheduled for September 30. This presentation will examine the effects of CagriSema on appetite and food cue reactivity in adults with overweight or obesity. It relies on functional MRI technology to observe specific brain responses. Novo Nordisk will also present data from the REIMAGINE 1 program.
That upcoming REIMAGINE 1 presentation will detail how the same medication affects body composition. It specifically looks at people living with early type 2 diabetes. Furthermore, the company plans to share a post-hoc analysis regarding patient-reported physical function. All of these planned presentations suggest that future obesity care may increasingly evaluate physical capability rather than scale weight alone.
Understanding these upcoming presentations requires looking at the biological mechanisms involved. CagriSema is an investigational once-weekly injectable treatment currently under study. It is a fixed-dose combination of two different active components. The first component is semaglutide, a well-known GLP-1 receptor agonist.
The second component is cagrilintide, a long-acting amylin analogue. Both GLP-1 and amylin are hormones naturally involved in digestion and satiety. Medications targeting these pathways help regulate blood sugar and slow stomach emptying. They also communicate directly with the brain to signal fullness.
This biological communication is crucial because weight management is never simply a matter of willpower. It involves complex interactions between our environment, habits and internal appetite signals. The planned functional MRI presentation will use non-invasive brain imaging to observe these precise interactions. Researchers use this technology to see which brain areas become active during specific tasks.
The planned study will observe how treatment alters neural responses when participants encounter food-related cues. This research could help clarify how the medication changes day-to-day hunger. Novo Nordisk is also developing a treatment called zenagamtide in both oral and subcutaneous forms. This unimolecular therapy was formerly known as amycretin.
Zenagamtide functions as a long-acting GLP-1 and amylin receptor agonist. The goal across these emerging metabolic medications is to provide comprehensive, multi-hormone approaches. By targeting multiple biological pathways, these treatments might address daily cravings more effectively. We are seeing a concerted effort to investigate biological effects far beyond simple scale weight.
These multi-hormone approaches reflect a growing understanding of how the body defends its weight. When someone attempts to lose weight through sheer dietary restriction, their appetite hormones typically surge. This biological response drives hunger higher and makes long-term maintenance incredibly difficult. By targeting multiple receptors simultaneously, pharmaceutical researchers aim to counteract this natural defense mechanism.
The upcoming presentations underscore why measuring total body weight is no longer sufficient. If a medication significantly reduces the urge to eat, patients might consume far fewer nutrients than their bodies require. This is why preserving muscle mass and skeletal health during treatment has become a major research priority. The new clinical data should help clarify whether these combination therapies protect physical function alongside weight reduction.
Mainstream media coverage often treats any new obesity medication data as a definitive breakthrough. We frequently see sensationalized headlines promising an immediate end to persistent cravings. The reality of clinical research is much more measured and complex. These are forthcoming data points from preliminary abstracts, not final conclusions.
When the new class of weight-loss medications dominated the news, the media reaction was entirely polarized. It was viewed as either an instant solution or a moral failing, which created a huge need for calm and objective reporting. Our team decided to cover these medications exactly like any other tool by examining the clinical data without judgment. The response from our readers showed just how starved people were for facts over feelings.
This objective approach is especially necessary when evaluating concepts like persistent cravings. The idea of food noise has gained immense popularity in current weight management discussions. However, this term lacks a standardized clinical definition in the recent announcement. It might refer broadly to intrusive thoughts about food, but the specific measurement instruments remain unclear.
A reported change in food-related thoughts does not automatically prove a universal improvement in eating habits. Martin Holst Lange serves as the chief scientific officer and executive vice president for Research and Development at Novo Nordisk. He noted that the company wants to investigate brain responses and body composition to improve patient outcomes. This statement outlines a corporate ambition rather than an independent confirmation of established clinical results.
Brain activation patterns shown on an MRI provide helpful mechanistic information. They do not guarantee that a patient will experience less snacking or a sustainable daily eating pattern. Furthermore, treatment comparisons often depend heavily on the specific endpoints being measured. Investor-focused reporting notes that CagriSema performed better than semaglutide but worse than Eli Lilly’s tirzepatide in a head-to-head weight-loss study.
That specific comparison only concerns total weight reduction on the scale. It does not establish which treatment is better for preserving lean mass, managing side effects or regulating daily hunger. The forthcoming data on body composition will require careful interpretation as well. Weight loss on a scale does not necessarily equate to improved metabolic health.
The planned REIMAGINE 1 analysis focuses specifically on body composition in participants with early type 2 diabetes. This specific population might experience different outcomes compared to adults without diabetes or people with normal weight. We must wait for the actual proportions of fat mass, visceral fat and lean mass changed with treatment to understand the full picture. Independent replication will ultimately be necessary to establish the reliability of all these upcoming findings.
Future research must clarify how these biological changes translate into everyday life. A reduction in appetite is a helpful tool, but long-term progress still depends on sustaining adequate nutrition. Patients and their healthcare providers will need complete publications and longer follow-up periods. We need to see if changes in brain responses to food cues lead to durable behavioral shifts.
We will be watching closely for specific data on organ-level fat and bone health. The company plans to share a post-hoc analysis on patient-reported physical function from the REDEFINE 1 program. Because this analysis is post-hoc, its findings should be interpreted as exploratory until confirmed by prospectively designed trials. Preserving physical function and skeletal strength is crucial for adults seeking sustainable health improvements.
Readers should look for independent confirmation of these findings outside of company-sponsored events. It is important to ask how any new treatment impacts hunger between meals, emotional eating and sleep quality. People considering these therapies should never select a medication based on a preliminary conference headline. Decisions about eligibility, dosing, side effects and continuation must be made with a qualified healthcare professional.
A practical framework involves tracking several lifestyle outcomes together instead of just focusing on weight. Patients should monitor meal satisfaction, strategies for appetite control, resistance-training consistency and medication adherence. The shift toward evaluating multi-hormone treatments represents a positive step for metabolic care. It acknowledges that effective weight management requires more than simple caloric restriction.
As the complete data emerges from the Milan conference, WeightRestart will prioritize reporting on what these medications change beyond the scale. Clear evidence on lean mass preservation and treatment tolerability will ultimately determine their value. We hope to see future trials that standardize terms like food noise to better support patient experiences. Until then, we will continue providing evidence-based translations of this rapidly evolving science.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
